Effectiveness of KarXT (Xanomeline-Trospium) for Cognitive Impairment in Schizophrenia: Post Hoc Analyses From a Randomised, Double-Blind, Placebo-Controlled Phase 2 Study

Sauder C, et al. Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study. Transl Psychiatry. 2022;12(1):491.